Optimising MS disease-modifying therapies: antibodies in perspective
- 1 September 2004
- journal article
- review article
- Published by Springer Nature in Zeitschrift für Neurologie
- Vol. 251 (5) , v30-v35
- https://doi.org/10.1007/s00415-004-1505-x
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosisBrain, 2003
- Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centreJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Neutralising antibodies to interferon beta during the treatment of multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2002
- The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-βJournal of Neuroimmunology, 2002
- Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratoryJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating diseaseThe FASEB Journal, 2002
- Bioequivalence and the immunogenicity of biopharmaceuticalsNature Reviews Drug Discovery, 2002
- Contrasting responses to interferon β‐1b treatment in relapsing‐remitting multiple sclerosis: Does baseline interleukin‐12p35 messenger RNA predict the efficacy of treatment?Annals of Neurology, 2000
- Letter from the EditorInternational Journal of MS Care, 2000
- A Novel Bioassay for the Determination of Neutralizing Antibodies to IFNβ1bJournal of Interferon & Cytokine Research, 1998